06/03/2025, 12:36 PM UTC
用于个性化癌症治疗的快速仿生纳米疫苗Rapid Biomimetic Nanovaccine for Personalized Cancer Therapy
➀ 研究开发了一种仿生纳米疫苗（AECM@PC7A），通过结合经干扰素-γ（IFN-γ）处理的肿瘤细胞膜与合成佐剂（PC7A），增强新抗原呈递并激活STING通路，以解决传统癌症疫苗的免疫原性不足和制造复杂等问题；
➁ 在临床前模型中，该疫苗显著激活T细胞免疫应答，抑制肿瘤生长和转移，并可与免疫检查点抑制剂协同作用，延长生存期并形成长期免疫记忆；
➂ 该平台利用肿瘤特异性新抗原与简化制造工艺，为个性化癌症免疫治疗提供了可扩展的方案，具有临床转化潜力。
➀ The study introduces a biomimetic nanovaccine (AECM@PC7A) that combines IFN-γ-treated tumor cell membranes with a synthetic adjuvant (PC7A) to enhance neoantigen presentation and activate the STING pathway, addressing limitations of conventional cancer vaccines;
➁ In preclinical models, the vaccine triggered robust T-cell responses, reduced tumor growth and metastasis, and demonstrated synergy with immune checkpoint inhibitors, leading to prolonged survival and immune memory;
➂ The platform offers a scalable approach for personalized immunotherapy by leveraging tumor-specific neoantigens and simplified manufacturing processes, showing promise for clinical translation.
---
本文由大语言模型（LLM）生成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。
